Skip to main content
. 2018 Dec 4;10(12):1916. doi: 10.3390/nu10121916

Table 5.

Summary of overall effects and subgroup analysis results for physical function

Subgroups Leg Muscle Strength Chair Rise Timed Up-and-Go
Comparison, n (LoE) a SMD (95%CI) p Value I2 (%) Comparison, n (LoE) a SMD (95%CI) p Value I2 (%) Comparison, n (LoE) a SMD (95%CI) p Value I2 (%)
Overall 15 (S) 0.37 (0.23, 0.51) <0.00001 37 9 (S) 0.30 (0.11, 0.49) 0.002 25 5 (S) 0.26 (0.02, 0.51) 0.04 32
MQ level (PEDro score)
≥7/10 12 (S) 0.38 (0.16, 0.60) 0.0006 50 4 (S) 0.32 (0.06, 0.59) 0.02 44 4 (C) 0.25 (−0.00, 0.50) n.s. 46
<7/10 3 (M) 0.39 (0.08, 0.70) 0.02 20 5 (M) 0.27 (0.01, 0.54) 0.04 23 1 (C) 0.57 (−0.69, 1.83) n.s. NA
Subgroup difference n.s. 0 n.s. 0 n.s. 0
Participant type
Community dweller 9 (S) 0.23 (0.05, 0.41) 0.01 0 5 (C) 0.22 (−0.11, 0.55) n.s. 45 3 (C) 0.25 (−0.03, 0.53) n.s. 64
Institutionalized resident 6 (S) 0.57 (0.36, 0.78) <0.00001 44 4 (M) 0.39 (0.08, 0.70) 0.01 0 2 (C) 0.29 (.23, 0.82) n.s. 0
Subgroup difference 0.01 83.2 n.s. 0 n.s. 0
Population area
Americas 2 (S) 1.02 (0.65, 1.40) <0.00001 0 0 1 (C) 0.23 (−0.34, 0.81) n.s. NA
Asia 3 (S) 0.28 (−0.09, 0.64) n.s. 39 0 3 (C) 0.25 (0.03, 0.53) n.s. 64
Europe 10 (S) 0.28 (0.11, 0.45) 0.001 0 8 (S) 0.31 (0.10, 0.51) 0.003 34 1 (C) 0.57 (−0.69, 1.83) n.s. NA
Oceania 0 1 (C) 0.25 (−0.26, 0.75) n.s. NA 0
Subgroup difference 0.002 84.5 n.s. 0 n.s. 0
Control group type
PLA-S or nonexercise 7 (S) 0.45 (0.24, 0.67) <0.0001 37 6 (S) 0.42 (0.19, 0.65) 0.0003 31 1 (C) 0.84 (0.33, 1.34) 0.001 NA
Exercise 13 (S) 0.20 (0.04, 0.36) 0.01 39 5 (S) 0.09 (−0.19, 0.36) n.s. 12 5 (C) −0.01 (−0.27, 0.25) n.s. 0
PS 4 (S) 0.30 (0.02, 0.59) 0.03 50 0 1 (M) 1.30 (0.77, 1.84) <0.00001 NA
Subgroup difference n.s. 20.4 n.s. 61.4 <0.0001 91.3
Supplementation dose
≥30 g/day (g/session) 8 (M) 0.40 (0.21, 0.59) 0.008 52 5 (S) 0.35 (0.10, 0.59) 0.005 42 0
<30 g/day (g/session) 7 (S) 0.34 (0.15, 0.53) 0.0004 22 4 (C) 0.34 (0.15, 0.53) n.s. 12 5 (S) 0.26 (0.02, 0.51) 0.04 32
Subgroup difference n.s. 0 n.s. 0 NA NA
Exercise type
RET 6 (M) 0.37 (0.04, 0.70) 0.03 57 4 (S) 0.29 (0.03, 0.56) 0.03 50 0
MET 9 (S) 0.37 (0.17, 0.58) 0.0004 24 5 (S) 0.31 (0.03, 0.58) 0.03 16 5 (S) 0.26 (0.02, 0.51) 0.04 32
Subgroup difference n.s. 0 n.s. 0 NA NA
Intervention duration
<12 weeks 5 (M) 0.58 (0.14, 1.01) 0.009 60 3 (C) −0.03 (−0.42, 0.36) n.s. 0 4 (C) 0.06 (−0.25, 0.37) n.s. 0
12–24 weeks 11 (S) 0.22 (0.06, 0.37) 0.006 10 6 (M) 0.23 (0.01, 0.45) 0.04 8 4 (M) 0.27 (0.01, 0.55) 0.04 49
≥24 weeks 5 (C) 0.21 (−0.03, 0.45) n.s. 0 5 (S) 0.14 (−0.35, 0.63) n.s. 75 0
Subgroup difference n.s. 16.7 n.s. 0 n.s. 0

Fixed-effects model. Random-effects model. a Level of evidence: strong (S), moderate (M), limited (L), very limited (V), conflicting (C). LoE, level of evidence; SMD, standard mean difference; I2, heterogeneity; MQ, methodological quality; PEDro, Physiotherapy Evidence Database; n.s., nonsignificant (p > 0.05); PLA-S, placebo supplement; PS, protein supplementation; RET, resistance exercise training; MET, multicomponent exercise training; NA, not applicable.